Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATXI Nasdaq 2834 http://www.avenuetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avenue Therapeutics Inc

Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights - Nov 4th, 2019 12:30 pm
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development - Oct 28th, 2019 12:30 pm
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting - Oct 18th, 2019 12:30 pm
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights - Aug 14th, 2019 11:30 am
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors - Aug 1st, 2019 12:00 pm
Avenue Therapeutics Trades Higher After Phase 3 Success - Jun 3rd, 2019 4:05 pm
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain - Jun 3rd, 2019 11:00 am
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights - May 13th, 2019 11:30 am
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors - Apr 30th, 2019 11:30 am
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights - Mar 12th, 2019 11:30 am
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) - Feb 11th, 2019 12:30 pm
ATXI: How Much Are CVRs Worth? - Jan 28th, 2019 3:05 pm
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI) - Jan 19th, 2019 11:45 pm
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain - Dec 19th, 2018 1:00 pm
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI - Dec 13th, 2018 1:00 am